Background: Pseudo exfoliation syndrome (PXS) widely in world occurred with various prevalence rate and its risk factor has main role in rising IOP and glaucoma. The aim of this study was to evaluate the relationship between PXS and its associations with elevation of IOP/Glaucoma.Methods: This is a cohort study that has been done on 144 patients of aged 50 and older referred to clinic of ophthalmology which was examined to the PXS depositions. PXS was diagnosed by slit lamp and a control group select matching with case group without PXS. All patients underwent a comprehensive ophthalmic evaluation by slit lamp and dilated pupil fundus for visual acuity, refraction, Tonometry and Gonioscopy.Results: Out of 144 eyes of control group, 112 (77.8%) had PXS depositions. There was a significant increase in number of PXS involved eyes with age and the frequency of disease in men was higher than women. Out of 72 patients, 40 (55.5%) patients were bilaterally and 32 (44.5%) patients were unilaterally involved. The mean of IOP in eyes with PXS with 17.9±8.9 was significantly higher than eyes without PXS with 14.5±2.9.Conclusions: PXS sediments are an important risk factor for increased IOP and glaucoma in our area and patients with PXS should be followed in term of IOP.
Birt–Hogg–Dubé (BHD) syndrome is an autosomal dominant disease that is manifested as benign cutaneous tumors, multiple lung parenchymal cysts and an increased risk of renal cancer. Its symptoms usually do not appear until adulthood. We report a patient who was admitted with recurrent pneumothorax. Discovering typical cutaneous lesions accompanied with a history of the same condition in his son, BHD syndrome was diagnosed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.